7月 2026LifeMine的市場佔有率分析

LifeMine is a clinical-stage biopharmaceutical company pioneering a bold new approach, Top-Down Drug DiscoveryTM, which leverages evolutionary insights from fungi to unearth next-generation precision medicines.

工作和職業 > 工作和就業

域名lifeminetx.com

成立年份2016

僱員51 - 200

年度營收$25M - $50M

LifeMine

LifeMine（包含公司地區）

lifeminetx.com

查看更多網站流量與參與度資訊

LifeMine截至 7月 2026 的總收入為 25M - 50M

LifeMine 熱門網域產生的總收入

LifeMine 熱門網域 3 年內的總收入

LifeMine 熱門網域的總收入

lifeminetx.com25M - 50M

透過銷售情報查看更多內容

LifeMine的熱門網域總造訪量

了解LifeMine市場觸達率與潛在市場影響力。

過去 3 個月的訪問總量

子公司細目

lifeminetx.com3.4K

透過銷售情報查看更多內容

LifeMine的熱門網域平均造訪時長

分析LifeMine參與度指標。

過去 3 個月平均造訪時長

子公司細目

lifeminetx.com00:00:14

透過銷售情報查看更多內容

LifeMine的熱門網域平均頁面瀏覽量

了解LifeMine如何保持使用者的參與度、培養其興趣，並鼓勵他們採取下一步。

過去 3 個月平均頁面瀏覽量

子公司細目

lifeminetx.com1.83

透過銷售情報查看更多內容

LifeMine按網域劃分的熱門競爭對手

看起來這裡的數據不足

無可顯示數據

使用的熱門技術LifeMine

这些是LifeMine顶级域名使用的行业网站技术

內容管理系統 (4)

WordPress

市場行銷 (2)

Google Marketing Platform

行動裝置 (2)

Meta Viewport

小工具 (2)

Twemoji

更多技術

5

檢視所有

新聞與訊號來自LifeMine

透過 Similarweb 銷售訊號提醒，每當目標受眾出現新的機會或威脅時，你就會收到每日更新的已識別購買訊號。

新聞LifeMine Therapeutics, Inc. received financing of $75M in Series D on Aug 26th '26.LifeMine Therapeutics announced $75 million in Series D and $188 million in Series E financing, totaling $263 million, to accelerate the clinical development of the company's lead program, LIFE-001, and advance its pipeline of transplantation and immunology therapies. LIFE-001 is a calcineurin activation inhibitor (CNai) delivered as a long-acting injectable and designed de novo to avoid the immunophilin-dependent organ damage associated with legacy calcineurin inhibitors (CNIs), such as cyclosporine, voclosporin, and tacrolimus.

新聞Lifeminetx hired Lata Jayaraman as chief medical officer and executive vice president of translational science on Dec 6th '22.LifeMine Therapeutics Inc., a biopharmaceutical company refashioning drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere, today announced the appointment of Elliot Ehrich, M.D., as chief medical officer and executive vice president of translational science, and of Lata Jayaraman, Ph.D., as executive vice president and head of biology.